Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

por Campioni, M., Agirrezabal, I., Hajek, R., Minarik, J., Pour, L., Spicka, I., Gonzalez-McQuire, S., Jandova, P., Maisnar, V.
Publicado 2019